On the HCPLive Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.
April 30th 2024
USPSTF now advises biennial breast cancer screening from age 40 to 74 years based on an evolving evidence base.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
May 21, 2024
Register Now!
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Multiple Myeloma from the Summer Meetings
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Oncology Briefings: How Do We Integrate New Data and Treatment Options to Optimize Outcomes for Patients with Hemolytic Anemias?
View More
Oncology Briefings™: Updates in the Care of Patients with ITP – Evaluating the Role of the Nurse
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical ShowCase™: Taking Control of Paroxysmal Nocturnal Hemoglobinuria
View More
Multidisciplinary Approach to Opioid Reduction Can Achieve Dosage Goals
In light of issues concerning opioid misuse running parallel to the tenfold increase of prescription opioid use over the past 20 years, a team of researchers have developed an ongoing study examining results of a pilot program aimed at reducing patients' use of pain medications.
FDA Limits Usage, Duration of Hyponatremia Drug Due to Observed Liver Damage Risk
Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.
FDA Approves Kcentra to Reverse Warfarin-Induced Anticoagulation
The US Food and Drug Administration (FDA) today approved Kcentra [prothrombin complex concentrate (human)] for the urgent reversal of anticoagulation induced by vitamin K antagonist (VKA) therapies such as warfarin in adult patients with acute major bleeding.
New Diabetes Management Guidelines Consider Concurrent Conditions
In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.
Adding Probiotic Compound to H. Pylori Eradication Treatment Doesn't Curb Adverse Effects
After noticing the ample adverse effects of second-line Helicobacter pylori eradication treatments that utilize tetracycline, furazolidone and proton-pump inhibitors, one group of gastroenterologists set to work adding a probiotic compound to the regimen in an attempt to increase the stomach bacteria's eradication rate while curbing those unwanted effects.
Pain Medicine Slowly Making Progress in Value-Based Care System
The advent of accountable care organizations, bundled payments, and other reforms under the Affordable Care Act has steered the focus of health care delivery from quantity to quality, but where exactly do pain medicine providers fit into the new value-based care model, and how can it benefit their patients?
Aubagio Decelerates Multiple Sclerosis Flare-Ups
Approved by the FDA in September 2012, Genzyme's Aubagio (teriflunomide tablets) is a once-daily oral treatment shown to reduce relapses, slow physical disability progression and reduce the number of brain lesions detected by magnetic resonance imaging (MRI) in patients with relapsing forms of multiple sclerosis (MS).
VIDEO: Many Heart Failure Patients Cannot Tolerate Recommended Doses of Beta Blockers
March 11th 2013Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.
Modern Technology Reveals Atherosclerosis Was Prevalent in Ancient Populations
March 11th 2013Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.
Researchers Tie Increased Acute Pancreatitis Risk to Cortisone Tablets
Though the causes of acute pancreatitis are unknown in roughly a quarter of its worldwide patient population, a recent analysis published in JAMA Internal Medicine has discovered a link between increased risk of the disease and medicines containing cortisone.
New Injectable Gel May Prevent Heart Failure After Myocardial Infarction
Bioengineers at the University of California, San Diego have deemed a new injectable hydrogel safe and effective for repairing tissue damage caused by myocardial infarction, providing a platform to bring the gel to clinical trials within the next year.